Chelsea Therapeutics International’s Buy Rating Reaffirmed at Ladenburg Thalmann (CHTP)
Chelsea Therapeutics International (NASDAQ:CHTP)‘s stock had its “buy” rating reaffirmed by equities research analysts at Ladenburg Thalmann in a research note issued to investors on Thursday, Analyst RN reports. They currently have a $4.00 target price on the stock. Ladenburg Thalmann’s price target would suggest a potential upside of 41.84% from the company’s current price.
Separately, analysts at Wedbush raised their price target on shares of Chelsea Therapeutics International from $7.00 to $8.00 in a research note to investors on Thursday. They now have an “outperform” rating on the stock.
Shares of Chelsea Therapeutics International (NASDAQ:CHTP) traded up 6.02% on Thursday, hitting $2.82. 1,545,997 shares of the company’s stock traded hands. Chelsea Therapeutics International has a 1-year low of $0.73 and a 1-year high of $3.30. The stock has a 50-day moving average of $3.0 and a 200-day moving average of $2.45. The company’s market cap is $189.4 million.
Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.